

**DESMOPRESSIN US  
DRUG SUBSTANCE SPECIFICATION**



Molecular weight: 1069 (as free base)

Page 1 of 2

Sequence: SCH<sub>2</sub>CH<sub>2</sub>CO-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH<sub>2</sub> Acetate salt

Last update: 09 SEP 2019

Available registration documents (CTD format): US DMF

TEST	ACCEPTANCE CRITERION	ANALYTICAL PROCEDURE
Appearance	A white powder	Visual inspection
Identity, Monoisotopic mass	1069.4 ± 0.5	USP
Identity, HPLC	The retention time of the major peak of the sample solution corresponds to that of the standard solution. The major peaks of the identity sample solution co-elute	In-house
Peptide content, HPLC	95.0-105.0% of Desmopressin calculated with reference to the anhydrous, acetic acid/acetate free substance	In-house
Peptide related impurities, HPLC		In-house
[Asp <sup>5</sup> ]desmopressin	≤ 0.4%	
[Glu <sup>4</sup> ]desmopressin	≤ 0.4%	
[Gly <sup>9</sup> OH]desmopressin	≤ 0.4%	
[L-Arg <sup>8</sup> ]desmopressin	≤ 0.4%	
[Gln <sup>4</sup> (Acm)]desmopressin and + [Asn <sup>5</sup> (Acm)]desmopressin	≤ 0.4%	
[Gly <sup>9</sup> N(CH <sub>3</sub> ) <sub>2</sub> ]desmopressin	≤ 0.4%	
Any unspecified impurity	≤ 0.3%	
Sum of impurities	< 1.5%	
Acetic acid content, HPLC	3.0 - 8.0%	USP
Water content, Karl Fischer titration	≤ 6.0% w/w	USP

**DESMOPRESSIN US  
DRUG SUBSTANCE SPECIFICATION**



Molecular weight: 1069 (as free base)

Page 2 of 2

Sequence: SCH<sub>2</sub>CH<sub>2</sub>CO-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH<sub>2</sub> Acetate salt

Last update: 09 SEP 2019

Available registration documents (CTD format): US DMF

<b>TEST</b>	<b>ACCEPTANCE CRITERION</b>	<b>ANALYTICAL PROCEDURE</b>
Residual solvents, Ethanol, GC	≤ 0.5%	In-house
Microbial enumeration tests:		USP
TAMC	≤ 100 CFU/g	
TYMC	≤ 100 CFU/g	
Bacterial endotoxins	< 500 EU/mg	USP